Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc. News
Nov 8, 2024 - accesswire.com
Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals
Aug 14, 2024 - globenewswire.com
Yield10 Bioscience Announces Second Quarter 2024 Financial Results
Jul 17, 2024 - globenewswire.com
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
Jul 17, 2024 - globenewswire.com
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
Yield10 Bioscience, Inc. Quantitative Score
About Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts.
Yield10 Bioscience, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Yield10 Bioscience, Inc. Financials
Table Compare
Compare YTEN metrics with: | |||
|---|---|---|---|
Earnings & Growth | YTEN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | YTEN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | YTEN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | YTEN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Yield10 Bioscience, Inc. Income
Yield10 Bioscience, Inc. Balance Sheet
Yield10 Bioscience, Inc. Cash Flow
Yield10 Bioscience, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Yield10 Bioscience, Inc. Executives
| Name | Role |
|---|---|
| Dr. Oliver P. Peoples Ph.D. | Co-Founder, President, Chief Executive Officer & Director |
| Ms. Lynne H. Brum | Vice President of Planning & Corporate Communications and Secretary |
| Mr. Charles B. Haaser CPA | Vice President of Finance, Chief Accounting Officer & Treasurer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Oliver P. Peoples Ph.D. | Co-Founder, President, Chief Executive Officer & Director | 1958 | 358.39K | |
| Ms. Lynne H. Brum | Vice President of Planning & Corporate Communications and Secretary | Female | 1964 | 287.14K |
| Mr. Charles B. Haaser CPA | Vice President of Finance, Chief Accounting Officer & Treasurer | Male | 1956 | 236.41K |
Yield10 Bioscience, Inc. Insider Trades
| Date | 15 Aug |
| Name | Snell Kristi |
| Role | VP Research and CSO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 877 |
| Date | 15 Aug |
| Name | BRUM LYNNE H |
| Role | VP Planning and Communications |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 731 |
| Date | 15 Aug |
| Name | HAASER CHARLES B |
| Role | VP Finance and CAO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 731 |
| Date | 15 Aug |
| Name | Peoples Oliver P |
| Role | President and CEO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 1463 |
| Date | 20 Dec |
| Name | SCHULER JACK W |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 36000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Aug | Snell Kristi | VP Research and CSO | Disposed | F-InKind | 877 |
| 15 Aug | BRUM LYNNE H | VP Planning and Communications | Disposed | F-InKind | 731 |
| 15 Aug | HAASER CHARLES B | VP Finance and CAO | Disposed | F-InKind | 731 |
| 15 Aug | Peoples Oliver P | President and CEO | Disposed | F-InKind | 1463 |
| 20 Dec | SCHULER JACK W | 10 percent owner | Disposed | S-Sale | 36000 |